MX2022005139A - Sales y formas de un modulador de receptores estrogénicos. - Google Patents
Sales y formas de un modulador de receptores estrogénicos.Info
- Publication number
- MX2022005139A MX2022005139A MX2022005139A MX2022005139A MX2022005139A MX 2022005139 A MX2022005139 A MX 2022005139A MX 2022005139 A MX2022005139 A MX 2022005139A MX 2022005139 A MX2022005139 A MX 2022005139A MX 2022005139 A MX2022005139 A MX 2022005139A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- salts
- forms
- receptor modulator
- receptor alpha
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000002834 estrogen receptor modulator Substances 0.000 title 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 abstract 3
- 102100038595 Estrogen receptor Human genes 0.000 abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930153P | 2019-11-04 | 2019-11-04 | |
| PCT/US2020/058526 WO2021091819A1 (en) | 2019-11-04 | 2020-11-02 | Salts and forms of an estrogen receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005139A true MX2022005139A (es) | 2022-06-24 |
Family
ID=75849360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005139A MX2022005139A (es) | 2019-11-04 | 2020-11-02 | Sales y formas de un modulador de receptores estrogénicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389006A1 (enExample) |
| EP (1) | EP4045507A4 (enExample) |
| JP (1) | JP2022553833A (enExample) |
| KR (1) | KR20220103977A (enExample) |
| CN (1) | CN114945570A (enExample) |
| AU (1) | AU2020380211A1 (enExample) |
| BR (1) | BR112022008520A2 (enExample) |
| CA (1) | CA3159749A1 (enExample) |
| IL (1) | IL292680A (enExample) |
| MX (1) | MX2022005139A (enExample) |
| TW (1) | TW202132294A (enExample) |
| WO (1) | WO2021091819A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2923412T3 (es) * | 2018-09-07 | 2022-09-27 | Sanofi Sa | Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas |
| CN114929696A (zh) | 2019-05-24 | 2022-08-19 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| PE20160874A1 (es) * | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| US20190142811A1 (en) * | 2016-04-01 | 2019-05-16 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| MX2022012828A (es) * | 2020-04-22 | 2023-01-04 | Recurium Ip Holdings Llc | Preparación de un degradador selectivo de receptores de estrógeno. |
-
2020
- 2020-11-02 US US17/755,562 patent/US20220389006A1/en not_active Abandoned
- 2020-11-02 BR BR112022008520A patent/BR112022008520A2/pt unknown
- 2020-11-02 CN CN202080093201.4A patent/CN114945570A/zh active Pending
- 2020-11-02 EP EP20885160.0A patent/EP4045507A4/en active Pending
- 2020-11-02 JP JP2022525923A patent/JP2022553833A/ja active Pending
- 2020-11-02 MX MX2022005139A patent/MX2022005139A/es unknown
- 2020-11-02 WO PCT/US2020/058526 patent/WO2021091819A1/en not_active Ceased
- 2020-11-02 AU AU2020380211A patent/AU2020380211A1/en active Pending
- 2020-11-02 CA CA3159749A patent/CA3159749A1/en active Pending
- 2020-11-02 KR KR1020227018944A patent/KR20220103977A/ko not_active Ceased
- 2020-11-03 TW TW109138322A patent/TW202132294A/zh unknown
-
2022
- 2022-05-02 IL IL292680A patent/IL292680A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3159749A1 (en) | 2021-05-14 |
| TW202132294A (zh) | 2021-09-01 |
| KR20220103977A (ko) | 2022-07-25 |
| EP4045507A1 (en) | 2022-08-24 |
| CN114945570A (zh) | 2022-08-26 |
| IL292680A (en) | 2022-07-01 |
| WO2021091819A1 (en) | 2021-05-14 |
| EP4045507A4 (en) | 2023-11-01 |
| AU2020380211A1 (en) | 2022-05-19 |
| US20220389006A1 (en) | 2022-12-08 |
| BR112022008520A2 (pt) | 2022-07-26 |
| JP2022553833A (ja) | 2022-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2019012532A (es) | Moduladores de k-ras. | |
| MX2020008767A (es) | Disruptores del dímero egfr y uso de estos. | |
| PH12021553000A1 (en) | Multispecific proteins | |
| PH12020500655A1 (en) | Compounds | |
| PH12021551950A1 (en) | Processes and compounds | |
| WO2020051142A3 (en) | Methods of treating cancer | |
| MX2016007282A (es) | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. | |
| MY203303A (en) | Compounds | |
| MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| JOP20200244B1 (ar) | مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان | |
| EP4616910A3 (en) | Pcna inhibitors | |
| EP4643950A3 (en) | Methods for treating testicular and ovarian adrenal rest tumors | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| WO2019143883A3 (en) | Compositions and methods for the treatment of cancer | |
| PH12017501151A1 (en) | Processes for the preparation of a diarylthiohydantoin compound | |
| MX2017013360A (es) | Métodos para tratar el cáncer. | |
| MX2021006102A (es) | Suministro mejorado de agentes grandes. | |
| EP4631539A3 (en) | Intraoperative uses of settable surgical compositions | |
| MX2020003388A (es) | Composiciones y metodos para tratar cancer hepatico. | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| WO2020086686A3 (en) | Compositions and methods for modulating factor viii function | |
| BR112022008520A2 (pt) | Sais e formas de um modulador de receptor de estrogênio |